Replies to post #141022 on Biotech Values

[DewDiligence]

Housekeeping note: A link to the table of Major FoB Collaborations now resides in the Tables and Compilations section of this board’s iBox.

[DewDiligence]

Daiichi Sankyo inks FoB collaboration with Coherus Biosciences (a new private company) for Enbrel and Rituxan knockoffs in certain Asian countries:

http://www.pharmatimes.com/Article/12-05-08/Coherus_launches_with_Daiichi_Sankyo_biosimilar_pact.aspx

[Coherus], which is headquartered in the San Francisco Bay Area and was founded in 2010, begins with a pipeline of five oncology and inflammatory disease therapeutics.

First to sign up is Daiichi Sankyo in a pact which will see the firms work together to advance biosimilar forms of the arthritis and psoriasis therapy Enbrel (etanercept) and the rheumatoid arthritis and cancer drug Rituxan (rituximab) developed by Coherus. Upon marketing approval, Daiichi Sankyo will commercialise these products in Japan, South Korea and Taiwan and specific financial terms of the agreement were not disclosed.

[DewDiligence]

Major FoB Collaborations

[Added entries for Merck KGaA-RDY and Daiichi-Coherus deals.]

 
                 Date   Targets  iHub References 
 Merck KGaA-RDY  6/12   oncology #msg-76359649 
 Daiichi-Coherus 5/12   *        #msg-75397629 
 Fujifilm-Kyowa  3/12   Humira   #msg-73800486 
 WPI-Bioton      2/12   insulin  #msg-74987123 
 WPI-AMGN       12/11   oncology #msg-70097496, #msg-70101928 
 BAX-MNTA       12/11   various  #msg-70212854, #msg-70258421 
 Samsung-BIIB   12/11   various  #msg-69629103 
 MRK-Hanwha      6/11   Enbrel   #msg-64164954, #msg-64193403  
 MYL-Biocon      6/09   various  #msg-39119393, #msg-72421544  
 TEVA-Lonza      1/09   various  #msg-34930012, #msg-34991518  
  
 *Enbrel and Rituxan in selected Asian countries.